Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.66 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | RECQL | P46063 | 1/20 | 0.64 |
| ▸ | BLM | P54132 | 1/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | FABP4 | P15090 | 1/20 | 0.56 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.52 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.52 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.52 |
| ▸ | TRPA1 | O75762 | 4/20 | 0.52 |
| ▸ | TRPM2 | O94759 | 2/20 | 0.52 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.52 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.52 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.52 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.52 |
| ▸ | MT-CO2 | P00403 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6480207 | 1.00 | SIRT2 (0.66) | SIRT2MEN1KMT2ARECQLBLM | |
| SCHEMBL6475772 | 0.90 | MEN1 (0.76) | SIRT2MEN1KMT2ARECQLBLM | |
| SCHEMBL6482855 | 0.88 | SIRT2 (0.77) | SIRT2MEN1KMT2ARECQLBLM | |
| SCHEMBL6475355 | 0.84 | MEN1 (0.69) | SIRT2MEN1KMT2ARECQLBLM | |
| SCHEMBL6475563 | 0.83 | SIRT2 (0.69) | SIRT2MEN1KMT2ARECQLBLM | |
| SCHEMBL13855746 | 0.81 | MEN1 (0.65) | SIRT2MEN1KMT2ARECQLBLM | |
| SCHEMBL6485787 | 0.81 | MEN1 (0.64) | SIRT2MEN1KMT2ARECQLBLM | |
| SCHEMBL6475644 | 0.81 | KMT2A (0.66) | SIRT2MEN1KMT2ARECQLBLM | |
| SCHEMBL6475426 | 0.81 | MEN1 (0.64) | SIRT2MEN1KMT2ARECQLBLM | |
| SCHEMBL6481765 | 0.81 | MEN1 (0.64) | SIRT2MEN1KMT2ARECQLBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6972287-B1 | Method of inhibiting amyloid protein aggregation and imaging amyloid deposits | PFIZER INC. (US) | 2005-12-06 | — | — | US | claimed |
| US-20040220235-A1 | Method of inhibiting amyloid protein aggregation and imaging amyloid deposits | AUGELLI-SZAFRAN CORINNE ELIZAB (US) | 2004-11-04 | — | — | US | claimed |
| CN-1378446-A | Method for inhibiting amyloid aggregation and imaging amyloid deposits | WARNER LAMBERT CO (US) | 2002-11-06 | — | — | CN | claimed |
| EP-1225886-A2 | METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS | WARNER-LAMBERT COMPANY (US) | 2002-07-31 | — | — | EP | claimed |
| WO-2000076489-A2 | METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS | WARNER-LAMBERT COMPANY (US) | 2000-12-21 | — | — | WO | claimed |
| US-6972287-B1 | Method of inhibiting amyloid protein aggregation and imaging amyloid deposits | PFIZER INC. (US) | 2005-12-06 | — | — | US | disclosed |
| US-20040220235-A1 | Method of inhibiting amyloid protein aggregation and imaging amyloid deposits | AUGELLI-SZAFRAN CORINNE ELIZAB (US) | 2004-11-04 | — | — | US | disclosed |
| CN-1378446-A | Method for inhibiting amyloid aggregation and imaging amyloid deposits | WARNER LAMBERT CO (US) | 2002-11-06 | — | — | CN | disclosed |
| EP-1225886-A2 | METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS | WARNER-LAMBERT COMPANY (US) | 2002-07-31 | — | — | EP | disclosed |
| WO-2000076489-A2 | METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS | WARNER-LAMBERT COMPANY (US) | 2000-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220235-A1 | Method of inhibiting amyloid protein aggregation and imaging amyloid deposits | APP, PSEN1, BACE1 | SIRT2 2735/4885MEN1 474/4885KMT2A 4729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.